{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T09:33:53Z","timestamp":1776332033284,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"National Research Council of Italy and the Italian Ministry of Health"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Interventions"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.jcin.2013.06.010","type":"journal-article","created":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T01:10:21Z","timestamp":1384996221000},"page":"1166-1175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Routine Assessment of On-Clopidogrel Platelet Reactivity and Gene Polymorphisms in Predicting Clinical Outcome Following Drug-Eluting Stent Implantation in Patients With Stable Coronary Artery Disease"],"prefix":"10.1016","volume":"6","author":[{"given":"Chiara","family":"Viviani Anselmi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Briguori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Roncarati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Papa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Visconti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia","family":"Focaccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"De Micco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael V.G.","family":"Latronico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Pagnotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluigi","family":"Condorelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcin.2013.06.010_bib1","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2013.06.010_bib2","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2013.06.010_bib3","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives","volume":"49","author":"Angiolillo","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.010_bib4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/dmd.109.029132","article-title":"Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite","volume":"38","author":"Kazui","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jcin.2013.06.010_bib5","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jacc.2009.04.084","article-title":"Pharmacogenetics in cardiovascular antithrombotic therapy","volume":"54","author":"Marin","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.010_bib6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2013.06.010_bib7","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2013.06.010_bib8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nm.2281","article-title":"Paraoxonase-1 is a major determinant of clopidogrel efficacy","volume":"17","author":"Bouman","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.jcin.2013.06.010_bib9","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/eurheartj\/ehn046","article-title":"Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation","volume":"29","author":"Price","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2013.06.010_bib10","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jacc.2011.06.059","article-title":"Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data","volume":"58","author":"Brar","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.jcin.2013.06.010_bib11","first-page":"S5","article-title":"Diagnosis and classification of diabetes mellitus","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.jcin.2013.06.010_bib12","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am J\u00a0Kidney Dis"},{"key":"10.1016\/j.jcin.2013.06.010_bib13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.thromres.2006.01.019","article-title":"Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study","volume":"119","author":"Malinin","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.jcin.2013.06.010_bib14","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.111.029165","article-title":"Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial","volume":"124","author":"Price","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2013.06.010_bib15","doi-asserted-by":"crossref","unstructured":"Sim SC, Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics 2010;4:278\u201381. Available at: http:\/\/www.cypalleles.ki.se. Accessed May 15, 2012.","DOI":"10.1186\/1479-7364-4-4-278"},{"key":"10.1016\/j.jcin.2013.06.010_bib16","doi-asserted-by":"crossref","unstructured":"Thorn CF, Klein TE, Altman RB. PharmGKB: the Pharmacogenomics Knowledge Base. Methods Mol Biol 2013;1015:311\u201320. Available at: http:\/\/www.pharmkb.org. Accessed May 15, 2012.","DOI":"10.1007\/978-1-62703-435-7_20"},{"key":"10.1016\/j.jcin.2013.06.010_bib17","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/S0735-1097(01)01702-8","volume":"38","author":"Cannon","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.010_bib18","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2013.06.010_bib19","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(04)16850-5","article-title":"A\u00a0hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents","volume":"364","author":"Babapulle","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2013.06.010_bib20","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"Optimal medical therapy with or without PCI for stable coronary disease","volume":"356","author":"Boden","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2013.06.010_bib21","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa0805796","article-title":"A\u00a0randomized trial of therapies for type 2 diabetes and coronary artery disease","volume":"360","author":"Frye","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2013.06.010_bib22","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jacc.2003.10.031","article-title":"The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease","volume":"43","author":"Sachdev","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.010_bib23","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1136\/hrt.2007.126649","article-title":"Comorbid conditions and outcomes after percutaneous coronary intervention","volume":"94","author":"Singh","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.jcin.2013.06.010_bib24","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1001\/jama.293.17.2126","article-title":"Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents","volume":"293","author":"Iakovou","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2013.06.010_bib25","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.jacc.2011.06.056","article-title":"Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database","volume":"58","author":"Tsai","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.010_bib26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1161\/CIRCINTERVENTIONS.109.924308","article-title":"Development and validation of risk adjustment models for long-term mortality and myocardial infarction following percutaneous coronary interventions","volume":"3","author":"Singh","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2013.06.010_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1161\/CIRCINTERVENTIONS.110.958389","article-title":"Value of age, creatinine, and ejection fraction (ACEF score) in assessing risk in patients undergoing percutaneous coronary interventions in the \u201cAll-Comers\u201d LEADERS trial","volume":"4","author":"Wykrzykowska","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2013.06.010_bib28","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jacc.2010.03.044","article-title":"Value of the SYNTAX score for risk assessment in the all-comers population of the randomized multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial","volume":"56","author":"Wykrzykowska","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.010_bib29","doi-asserted-by":"crossref","first-page":"942","DOI":"10.4244\/EIJV6I8A164","article-title":"An\u00a0integer based risk score for predicting 30-day major adverse cardiac or\u00a0cerebrovascular events after percutaneous coronary intervention with\u00a0drug-eluting stents: results from a large prospective multicentre registry, the STENT Group","volume":"6","author":"Ito","year":"2011","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2013.06.010_bib30","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJMoa0804626","article-title":"Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease","volume":"360","author":"Serruys","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2013.06.010_bib31","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2013.06.010_bib32","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.amjcard.2008.11.048","article-title":"Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis","volume":"103","author":"Giusti","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcin.2013.06.010_bib33","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","article-title":"Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents","volume":"51","author":"Trenk","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.010_bib34","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/clpt.2011.132","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy","volume":"90","author":"Scott","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcin.2013.06.010_bib35","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2013.06.010_bib36","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.jacc.2011.11.068","article-title":"Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study","volume":"59","author":"Price","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.010_bib37","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and\u00a0CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2013.06.010_bib38","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/eurheartj\/ehp041","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention","volume":"30","author":"Sibbing","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2013.06.010_bib39","unstructured":"Stone G. ADAPT-DES: a large-scale, prospective, multicenter registry examining the relationship of platelet responsiveness and stent thrombosis after DES implantation. Presented at: TCT Meeting 2011. Available at: http:\/\/tv.clinicaltrialresults.org\/play.php?submission_id=1067. Accessed May 15, 2012."},{"key":"10.1016\/j.jcin.2013.06.010_bib40","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ahj.2007.10.046","article-title":"The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial","volume":"155","author":"Best","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcin.2013.06.010_bib41","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.2337\/diabetes.54.8.2430","article-title":"Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment","volume":"54","author":"Angiolillo","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.jcin.2013.06.010_bib42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jcin.2008.06.012","article-title":"In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry","volume":"2","author":"Latif","year":"2009","journal-title":"J\u00a0Am Coll Cardiol Interv"},{"key":"10.1016\/j.jcin.2013.06.010_bib43","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jacc.2007.04.051","article-title":"Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry","volume":"50","author":"Machecourt","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.010_bib44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ahj.2012.10.013","article-title":"Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention","volume":"165","author":"Park","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcin.2013.06.010_bib45","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/eurheartj\/ehr479","article-title":"Lower risk of stent thrombosis and restenosis with unrestricted use of \u201cnew-generation\u201d drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR)","volume":"33","author":"Sarno","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2013.06.010_bib46","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"Trenk","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.010_bib47","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2013.06.010_bib48","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2008.11.030","article-title":"Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis","volume":"53","author":"Sibbing","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2013.06.010_bib49","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jama.2011.1332","article-title":"High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI","volume":"306","author":"Parodi","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2013.06.010_bib50","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.jacc.2010.12.047","article-title":"Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome","volume":"57","author":"Campo","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["JACC: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879813013514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879813013514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:59:59Z","timestamp":1761847199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936879813013514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S1936879813013514"],"URL":"https:\/\/doi.org\/10.1016\/j.jcin.2013.06.010","relation":{},"ISSN":["1936-8798"],"issn-type":[{"value":"1936-8798","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Routine Assessment of On-Clopidogrel Platelet Reactivity and Gene Polymorphisms in Predicting Clinical Outcome Following Drug-Eluting Stent Implantation in Patients With Stable Coronary Artery Disease","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcin.2013.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}